FIGURE 2:
Autocrine TGF-β signaling is required for the maintenance of a mesenchymal state. (A) Real-time PCR measurements of TGF-β family members after exogenous TGF-β1 treatment of MDCK cells. TGF-β3 levels were not detected (N.D.) in untreated MDCK cells. Data are normalized to untreated levels for TGF-β1 and TGF-β2 or Day 2 levels for TGF-β3. (B) TGF-β1 and TGF-β2 secreted by MDCK and MDCK-TGF cells into the culture medium was measured by ELISA. A TGF-β3 ELISA was not available for measurement of secreted TGF-β3. (C) Real-time PCR measurement of ZEBs in MDCK-TGF cells after inhibition of TGF-β signaling using the TGF-βRI inhibitor (1 μM SB-505124; 13 d) (D) Immunofluorescence staining of E-cadherin (red) and ZO-1 (green), and rhodamine phalloidin staining of F-actin in MDCK-TGF cells either untreated or treated with a TGF-βRI inhibitor [as in (C)] or a TGF-β1/2/3 neutralizing antibody (100 μg/ml; 15 d). Cells are counterstained with DAPI to visualize nuclei. Scale bars = 50 μm. (E) Quantitation of miR-200 levels in MDCK-TGF cells treated with individual TGF-β1, -β2, -β3 and -β1/2/3 neutralizing antibodies (100 μg/ml) after 7 or 15 d of treatment. Values are the mean ± SD of three replicate measurements.
